LENSAR (LNSR) Stock Forecast: StockMap's 2-Week Call
LNSR stock forecast: StockMap's model leans Underperform on LENSAR for the two weeks after the Nov 13 close, toward LNSR trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 3 two-week windows on LNSR since Sep 24; by chance, a call on the same dates was right 51% of the time.
LENSAR last closed at $5.00, +6.38% on the session.
Against the IVW growth benchmark the position is +7.29% over the forecast window.
LENSAR's market cap is $61.47M as of November 13, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -21 (too close to call).
Where LNSR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 6 bullish and 9 bearish.
Agreement across those insights is 60%.
20 daily calls for LNSR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks LENSAR in the 99th percentile on return on equity, where 100 is best.
LENSAR is classified under Health Care / Health Care Equipment & Supplies.
StockMap tracks LENSAR as the 110th largest of the 142 companies it covers in the Health Care Equipment & Supplies industry, part of the Health Care sector.
Across that group the current two-week reads are 74 Neutral, 52 Moderate Underperform, 13 Strong Underperform and 3 Moderate Outperform.
On that composite LENSAR ranks 83rd of 142 in the group, against a group median of -0.15.